Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of subcutaneous PL 3994 for the treatment of acute decompensated heart failure

Next Previous
X
Search
Trial Profile

Phase II trial of subcutaneous PL 3994 for the treatment of acute decompensated heart failure

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PL 3994 (Primary)
  • Indications Decompensated heart failure
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Palatin Technologies

    • Most Recent Events

    • 21 Jan 2020 According to a Palatin Technologies media release, the study is anticipated to start patient enrollment in 2020.
    • 21 Jan 2020 According to a Palatin Technologies media release, this trial is part of a collaboration with two major academic medical centers.
    • 01 Jul 2019 According to a Palatin Technologies media release, this trial is supported by a grant from the American Heart Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top